Unit
Dermatologie | Venerologie | Allergologie
DERMA · Interdisciplinary Medical Services
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
Jul 11, 2022
Clinical Studies - Jul 11, 2022 - Dec 31, 2026
Ongoing
Project leader: Wagner Nikolaus
Two cohort registry study for patients with advanced CSCC treated with Cemiplimab or other approaches
Jul 1, 2022
Clinical Studies - Jul 1, 2022 - Dec 31, 2025
Ongoing
Project leader: Wagner Nikolaus
Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)
Feb 14, 2022
Clinical Studies - Feb 14, 2022 - Dec 31, 2025
Ongoing
Project leader: Cozzio Antonio
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study
Jan 25, 2022
Clinical Studies - Jan 25, 2022 - Jan 25, 2022
Automatically Closed
Project leader: Cozzio Antonio
A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study
Jan 18, 2022
Clinical Studies - Jan 18, 2022 - Dec 31, 2024
Ongoing
Project leader: Saulite Ieva
Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate -to -severe plaque psoriasis and inadequate response to ustekinumab; COBRA / Phase 4 – efficacy trial A randomised, blinded, parallel-group, multi-site, clinical trial
Sep 13, 2021
Clinical Studies - Sep 13, 2021 - Nov 16, 2022
Completed
Project leader: Cozzio Antonio
Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland – BERINGMELANOMA
Sep 7, 2021
Clinical Studies - Sep 7, 2021 - Oct 1, 2027
Ongoing
Project leader: Wagner Nikolaus
Development of the European Organisation for Research and Treatment of Cancer (EORTC)/ Cutaneous Lymphoma Task Force (CLTF) questionnaire to assess HRQoL in cutaneous lymphoma
Feb 1, 2021
Clinical Studies - Feb 1, 2021 - Aug 25, 2023
Ongoing
Project leader: Cozzio Antonio
Translation of pre-treatment tumor kinetics and clinical and serological markers of the immune system in the treatment of advanced melanoma
Jan 1, 2021Bei diesem Projekt geht es um die Charakterisierung des Therapieansprechens von Melanommetastasen unter Systemtherapie mit anti-PD-1 Antikörpern, kombinierter Immuntherapie mit dem anti-PD-1 Antikörper Nivolumab und dem anti-CTLA-4 Antikörper Ipilimu...
Clinical Studies - Jan 1, 2021 - Dec 31, 2021
Completed
Project leader: Wagner Nikolaus
PH-L19IL2TNFNMSC-04/19 A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions
Aug 2, 2020
Clinical Studies - Aug 2, 2020 - Jan 25, 2030
Ongoing
Project leader: Flatz Lukas
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)
Jul 15, 2016
Clinical Studies - Jul 15, 2016 - Oct 15, 2019
Automatically Closed
Project leader: Flatz Lukas
Members: Diem Stefan
A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
Jun 25, 2016
Clinical Studies - Jun 25, 2016 - Dec 31, 2027
Ongoing
Project leader: Cozzio Antonio
Vaccine and immunotherapy induced CD8+ T cell responses against auto-, neo- and foreign antigens
Jan 1, 2016The growing incidence of melanoma is an increasing threat, and effective treatment options for advanced forms of melanoma are scarce. Although recently approved targeted- and immunotherapies have shown objective beneficial effects in metastatic melan...
Fundamental Research - Jan 1, 2016 - Dec 31, 2019
Automatically Closed
Project leader: Flatz Lukas
Members: Ring Sandra, Królik Michał Wojciech, Berner Fiamma
Long-Term Benefits and Safetyof Systematic Psoriasis Therapy: Swiss Registry on the Treatment of System Psoriasis with Biologics and Systemic Therapeutigs based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
Jul 19, 2012
Clinical Studies - Jul 19, 2012 - Jul 19, 2012
Automatically Closed
Project leader: Anliker Mark
Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions
May 19, 2012Purpose: A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions
Clinical Studies - May 19, 2012 - Jun 19, 2013
Automatically Closed
Project leader: Anliker Mark
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Feb 19, 2012The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and ad...
Clinical Studies - Feb 19, 2012 - Jun 19, 2013
Automatically Closed
Project leader: Anliker Mark
Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
Jan 31, 2012
Clinical Studies - Jan 31, 2012 - Dec 31, 2030
Ongoing
Project leader: Cozzio Antonio
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Nov 15, 2011Purpose: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Clinical Studies - Nov 15, 2011 - Dec 1, 2013
Automatically Closed
Project leader: Anliker Mark
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Nov 15, 2011The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the q...
Clinical Studies - Nov 15, 2011 - Apr 19, 2015
Automatically Closed
Project leader: Anliker Mark
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Oct 19, 2011This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Clinical Studies - Oct 19, 2011 - Sep 19, 2012
Automatically Closed
Project leader: Anliker Mark